Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms

International Urogynecology Journal

Volumn 18, Issue 7, 2007, Pages 737-741

  Brubaker, Linda ^a   FitzGerald, Mary P ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cohort studies; Lower urinary tract; Muscarinic antagonists; Nocturia; Nocturnal polyuria; Urinary incontinence

Indexed keywords

PLACEBO; SOLIFENACIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGHT; NOCTURIA; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY FREQUENCY;

EID: 34347406127     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-006-0239-y     Document Type: Article

References (20)

1. van Kerrebroeck P, Abrams P, Chaikin D et al (2002) The standardisation of terminology in nocturia: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:179-183
2. Lundgren R (2004) Nocturia: A new perspective on an old symptom. Scand J Urol Nephrol 38:112-116
3. Svatek R, Roche V, Thornberg J, Zimmern P (2005) Normative values for the American Urological Association Symptom Index (AUA-7) and short form Urogenital Distress Inventory (UDI-6) in patients 65 and older presenting for non-urological care. Neurourol Urodyn 24:606-610
4. Asplund R, Marnetoft SU, Selander J, Akerstrom B (2005) Nocturia in relation to somatic health, mental health and pain in adult men and women. BJU Int 95:816-819
5. Kobelt G, Borgstrom F, Mattiasson A (2003) Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 91:190-195
6. Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E (2003) The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92:948-954
7. Stewart RB, Moore MT, May FE, Marks RG, Hale WE (1992) Nocturia: A risk factor for falls in the elderly. J Am Geriatr Soc 40:1217-1220
8. Asplund R (1999) Mortality in the elderly in relation to nocturnal micturition. BJU Int 84:297-301
9. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178
10. Cardozo L, Lisec M, Millard R et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919-1924
11. Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303-310
12. Gittelman M, Chu F, Klimberg I, Fincher R, Smith N, Tempel D, Ridge S (2003) Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 (solifenacin succinate; Vesicare®) versus placebo in male and female subjects with overactive bladder. Poster presented at the American Urological Association Annual Meeting; April 26-May 1, 2003; Chicago, IL (on behalf of the YM905 Study Group)
13. van Elteren PH (1960) On the combination of independent two-sample tests of Wilcoxon. Bull Inst Int Stat 37:351-361
14. Weiss JP, Blaivas JG (2000) Nocturia. J Urol 163:5-12
15. Drake NL, Flynn MK, Romero AA, Weidner AC, Amundsen CL (2005) Nocturnal polyuria in women with overactive bladder symptoms and nocturia. Am J Obstet Gynecol 192:1682-1686
16. Weiss JP, Blaivas JG, Stember DS, Brooks MM (1998) Nocturia in adults: etiology and classification. Neurourol Urodyn 17:467-472
17. Johnson TM II, Burgio KL, Redden DT, Wright KC, Goode PS (2005) Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 53:846-850
18. Kreder KJ Jr, Brubaker L, Mainprize T (2003) Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 92:418-421
19. Chapple C, Steers W, Norton P et al (2005) A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M selective receptor antagonist, in the treatment of overactive bladder. BJU Int 95:993-1001
20. Hill S, Khullar V, Wyndaele JJ, Lheritier K (2005) Dose response with darifenacin, a novel once-daily M(3) selective receptor antagonist for the treatment of overactive bladder: Results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 17(3):239-247